BioLight Israeli Life Sciences Investments
BioLight Life Sciences Ltd. is a leading company investing in companies and managing projects relating to eye disease and their treatment. BioLight’s portfolio companies engage in advanced medical devices, medication, diagnostics and digital medicine and all exemplify the enormous potential of Israeli innovation in these fields. Development and commercialization of the company’s ophthalmic technologies and products. The ophthalmic products developed by the companies in the BioLight group are aimed at innovative diagnosis and treatments for the needs of patient groups suffering from eye diseases. The different ophthalmic products are in various commercialization and clinical (or pre-clinical) phases. BioLight intends, in line with its financial capabilities, to continue supplementing and expanding the array of technologies and products under development, whether through investment in additional companies or through business development and expansion of the activity of the existing companies.
BELKIN Vision
Series B in 2020
BELKIN Vision focuses on developing a laser device that aids healthcare professionals in the treatment of glaucoma. The company's technology offers a non-invasive, non-contact, instantaneous, painless, and automated approach to laser therapy. By promoting accessibility to first-line drop-less glaucoma care, BELKIN Vision enables any ophthalmologist to effectively treat patients. This innovation aims to enhance treatment outcomes and improve the overall quality of care for individuals suffering from glaucoma.
Ioptima
Venture Round in 2015
IOPtima Ltd. specializes in the development of minimally-invasive surgical ophthalmic devices, primarily focusing on glaucoma treatment. The company's flagship product, the IOPtimate, is a CO2 laser-based surgical system designed to reduce internal eye pressure by restoring natural fluid flow without penetrating the eye. This innovative approach addresses common safety issues associated with glaucoma surgery and enhances surgical outcomes. IOPtima has also developed a procedure known as CLASS (CO2 Laser-Assisted Sclerotomy Surgery), which utilizes the unique properties of CO2 laser technology to thin the scleral wall in a controlled manner. This technique allows for effective treatment while minimizing side effects and recovery time. Founded in 2002 and based in Tel Aviv, Israel, IOPtima operates as a subsidiary of Bio Light Israeli Life Sciences Investments Ltd.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.